Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Total Liabilities (2016 - 2025)

Cardiff Oncology's Total Liabilities history spans 15 years, with the latest figure at $16.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 15.83% year-over-year to $16.5 million; the TTM value through Dec 2025 reached $16.5 million, up 15.83%, while the annual FY2025 figure was $16.5 million, 15.83% up from the prior year.
  • Total Liabilities for Q4 2025 was $16.5 million at Cardiff Oncology, up from $15.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $17.1 million in Q2 2025 and bottomed at $4.8 million in Q1 2021.
  • The 5-year median for Total Liabilities is $10.8 million (2022), against an average of $11.4 million.
  • The largest annual shift saw Total Liabilities fell 16.2% in 2021 before it soared 123.98% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $9.1 million in 2021, then rose by 7.9% to $9.8 million in 2022, then rose by 20.82% to $11.9 million in 2023, then grew by 19.69% to $14.2 million in 2024, then increased by 15.83% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Total Liabilities are $16.5 million (Q4 2025), $15.0 million (Q3 2025), and $17.1 million (Q2 2025).